Taming the Autophagy as a Strategy for Treating COVID-19

BE García-Pérez, JA González-Rojas, MI Salazar… - Cells, 2020 - mdpi.com
Currently, an efficient treatment for COVID-19 is still unavailable, and people are continuing
to die from complications associated with SARS-CoV-2 infection. Thus, the development of …

Systemic lupus erythematosus and COVID-19

M Pappa, A Panagiotopoulos, K Thomas… - Current Rheumatology …, 2023 - Springer
Abstract Purpose of Review To describe the current state of knowledge regarding COVID-19
in patients with systemic lupus erythematosus (SLE). We focus on (i) SARS-CoV-2 …

RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial

HM Dabbous, MH El-Sayed, G El Assal, H Elghazaly… - Scientific reports, 2021 - nature.com
Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different
viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of …

Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic

EG Favalli, G Maioli, M Biggioggero… - Expert Review of …, 2021 - Taylor & Francis
ABSTRACT Introduction: Coronavirus disease 2019 (COVID-19) pandemic raises a great
challenge in the management of patients with rheumatoid arthritis (RA), which are generally …

Adventitial microcirculation is a major target of SARS-CoV-2-mediated vascular inflammation

F Vasuri, C Ciavarella, S Collura, C Mascoli, S Valente… - Biomolecules, 2021 - mdpi.com
We report the case of a 77-year-old woman affected by coronavirus disease-19 (COVID-19)
who developed an occlusive arterial disease of the lower limb requiring a left leg …

Profiles of independent-comorbidity groups in senior COVID-19 patients reveal low fatality associated with standard care and low-dose hydroxychloroquine over …

KB Said, A Alsolami, FS Alreshidi… - Journal of …, 2023 - Taylor & Francis
Introduction The lack of feasible therapies and comorbidities aggravate the COVID-19 case–
fatality rate (CFR). However, reports examining CFR associations with diabetes, concomitant …

An internet-based cross-sectional study on infection control practices and drug use for COVID-19 prevention in Nigerian adults

AO Ogunyemi, AW Olusanya, AP Arikawe… - Pan African Medical …, 2022 - ajol.info
Introduction: COVID-19 has affected several millions of people globally and various means
have been employed to curb the spread. This nationwide survey investigated adherence to …

[HTML][HTML] Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre

I Istampoulouoglou, B Zimmermanns… - … Cardiology Science & …, 2021 - ncbi.nlm.nih.gov
In this article we summarize the cardiovascular adverse events that were observed in three
patients during their treatment for COVID-19 and discuss their association with …

[HTML][HTML] The utilization of hydroxychloroquine to reduce the main signs and symptoms of COVID-19 patients, a cross-sectional study

S Alsuwaidan, ZA Memish, F Alaklobi, K Khan… - Annals of Medicine and …, 2021 - Elsevier
Hydroxychloroquine (HCQ) and chloroquine were found to have positive results in some
non-randomized clinical trials with more benefit in decreasing the viral load of COVID-19 …

[PDF][PDF] COVID-19 special issue editorial

AD Kaye, L Manchikanti - Pain Physician, 2020 - painphysicianjournal.com
Pain Physician 2020; 23: S149-S159• ISSN 2150-1149 is unprecedented. Almost all health
care professionals lost revenues in April, May and June amid social distancing measures …